Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02757313 · ClinicalTrials.gov registry record · Phase 1
Neuroscience of Marijuana Impaired Driving
A Phase 1 study of Marijuana Impairment, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT02757313 is a Phase 1 study of Marijuana Impairment that has completed, run by Yale University. The registered enrollment target is 62 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02757313, a Phase 1 study of Marijuana Impairment, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Marijuana is one of the most widely used substances. However, marijuana intoxication is not fully understood in relation to driving. This study will help the investigators learn more about the potential impairments related to marijuana intoxicated driving. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure intoxication and impairment. This study will also assess levels of marijuana in blood and saliva samples. This study takes place in Hartford, Connecticut.
Conditions Studied
Interventions
- DRUG Low dose THC marijuana
- DRUG High dose THC marijuana
- DRUG Placebo marijuana
Study Locations (1)
Connecticut
- Olin Neuropsychiatry Research Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02757313
The ClinicalTrials.gov registry entry for NCT02757313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marijuana Impairment appearing as the primary indexed condition, and to 3 interventions - of which Low dose THC marijuana is the first listed.
NCT02757313 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02757313 about?
NCT02757313 is a clinical study titled "Neuroscience of Marijuana Impaired Driving". Marijuana is one of the most widely used substances. However, marijuana intoxication is not fully understood in relation to driving. This study will help the investigators learn more about the potential impairments related to marijuana intoxicated driving. A combination of MRI and neuropsychological...
What is the current status of trial NCT02757313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-10. Estimated completion is 2021-05.
What conditions does trial NCT02757313 study?
This clinical trial studies the following conditions: Marijuana Impairment.
What interventions are being tested in trial NCT02757313?
The interventions under investigation include: Low dose THC marijuana (DRUG), High dose THC marijuana (DRUG), Placebo marijuana (DRUG).
Who is sponsoring clinical trial NCT02757313?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02757313 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.